Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/09/2020 8-K Quarterly results
Docs: "BioSpecifics Reports Third Quarter 2020 Financial and Operating Results"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/16/2020 8-K Quarterly results
08/09/2019 8-K Quarterly results
05/10/2019 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results - 14% year-over-year increase for BioSpecifics first quarter royalty revenues for XIAFLEX - - Phase 1 clinical trial of uterine fibroids completed - - BLA filing for XIAFLEX for treatment of cellulite expected in 2H19 -"
04/02/2019 8-K Quarterly results
Docs: "Press Release"
11/09/2018 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results"
08/09/2018 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results"
03/14/2018 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results LYNBROOK, NY - March 14, 2018 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2017 and provided a corporate update. “2018 is off to a solid start with the Phase 3 cellulite trials for CCH now initiated and positive interim data recently presented for our ongoing Phase 1 uterine fibroids trial, which is advancing toward a top-line data readout this year. In 2017, we continued to be pleased with our royalty revenues from XI..."
11/13/2017 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial Results"
08/09/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Condensed Consolidated Income Statement"
05/10/2016 8-K Form 8-K - Current report
03/14/2016 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Consolidated Statements of Operations Three months ended Twelve months ended December 31 December 31 2015 2014 2015 2014 Revenues: Royalties 5,226,523 4,135,303 20,800,757 12,985,370 Licensing revenue 912,344 512,345 1,949,378 1,059,254 Total Revenues 6,138,867 4,647,648 22,750,135 14,044,624 Costs and expenses: Research and development 279,250 354,383 1,034,288 1,263,512 General and administrative 1,965,101 1,427,051 7,272,532 5,814,185 Total costs and expenses 2,244,351 1,781,434 8,306,820 7,077,697 Operating income 3,894,516 2,866,214 14,443,315 6,966,927 Other income: Interest Income 33,980 9,714 92,926 32,158 Other, net 8,609 2,837 14,719 33,582 42,589 12,551 107,645 65,740 Income before provision for income taxes 3,937,105 2,878,765 14,550,960 7,032,6...",
"BioSpecifics Technologies Corp. Consolidated Statements of Operations Three months ended Twelve months ended December 31 December 31 2015 2014 2015 2014 Revenues: Royalties 5,226,523 4,135,303 20,800,757 12,985,370 Licensing revenue 912,344 512,345 1,949,378 1,059,254 Total Revenues 6,138,867 4,647,648 22,750,135 14,044,624 Costs and expenses: Research and development 279,250 354,383 1,034,288 1,263,512 General and administrative 1,965,101 1,427,051 7,272,532 5,814,185 Total costs and expenses 2,244,351 1,781,434 8,306,820 7,077,697 Operating income 3,894,516 2,866,214 14,443,315 6,966,927 Other income: Interest Income 33,980 9,714 92,926 32,158 Other, net 8,609 2,837 14,719 33,582 42,589 12,551 107,645 65,740 Income before provision for income taxes 3,937,105 2,878,765 14,550,960 7,032,6..."
11/09/2015 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Third Quarter 2015 Financial Results"
08/10/2015 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Condensed Consolidated Income Statement"
05/11/2015 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results"
03/13/2015 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 Financial Results"
11/10/2014 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Third Quarter 2014 Financial Results - Auxilium to exercise the exclusive option to expand the field of its license of CCH to include the potential treatment of canine lipoma LYNBROOK, NY - November 10, 2014 - BioSpecifics Technologies Corp. , a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® in the U.S. and XIAPEX ® in the EU, today announced its financial results for the third quarter ended September 30, 2014 and provided a corporate update. “The third quarter was marked by considerable progress across our commercial and clinical programs and we continue to focus on expanding the potential of XIAFLEX. We were very excited to announce last month the FDA-approved label expansion in Dupuytren's cont..."
08/11/2014 8-K Quarterly results
Docs: "Letter from Tabriztchi & CO., CPA, P.C.",
"BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results LYNBROOK, NY - August 11, 2014 - BioSpecifics Technologies Corp. , a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update. “This was a momentous quarter of milestones for XIAFLEX both commercially and clinically. We saw significant growth in revenues from XIAFLEX U.S. sales, most notably in Peyronie's disease. We are particularly pleased to see the number of vials shipped in the second quarter of 2014; 565 in April, 775 in May and then almost double that number in June with 1,412 vials shipped. This was a significant incr..."
05/08/2014 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports First Quarter 2014 Financial Results"
03/06/2014 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Consolidated Statements of Operations"
11/12/2013 8-K Form 8-K - Current report
08/08/2013 8-K Quarterly results
Docs: "6 7"
05/10/2013 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results LYNBROOK, NY - May 10, 2013 - BioSpecifics Technologies Corp. , a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX ® in the U.S., today reported its financial results for the first quarter ended March 31, 2013 and provided a corporate update. “We are very pleased to have completed enrollment in our Phase II trials in canine and human lipoma and we remain on track to report top-line data for both trials in the second half of this year,” reflected Thomas L. Wegman, President of BioSpecifics. “In addition, there are a number of exciting upcoming milestones for XIAFLEX this year. We are looking forward to the potential approval of XIAFLEX for the treatment of Peyronie'..."
03/12/2013 8-K Form 8-K - Current report
11/08/2012 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results",
"BioSpecifics Technologies Corp. Announces Submission of Supplemental Biologics License Application to FDA for XIAFLEXfor Treatment of Peyronie's Disease"
08/09/2012 8-K Form 8-K - Current report
05/10/2012 8-K Form 8-K - Current report
03/09/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy